AI assistant
Sending…
KIORA PHARMACEUTICALS INC — Director's Dealing 2017
Jun 22, 2017
35256_dirs_2017-06-22_b66ae15d-8da9-4a18-a69b-1fe78ab8f4e3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: EYEGATE PHARMACEUTICALS INC (EYEG)
CIK: 0001372514
Period of Report: 2017-06-21
Reporting Person: Romano Sarah (Interim CFO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-06-21 | Stock Option (right to buy) | $1.35 | A | 40000 | Acquired | 2027-06-21 | Common Stock (40000) | Direct |
Footnotes
F1: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on June 21, 2018, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.
More from KIORA PHARMACEUTICALS INC
Share Issue/Capital Change
2026
May 28
Regulatory Filings
2026
May 18
Earnings Release
2026
May 8
Interim / Quarterly Report
2026
May 8
Annual Report
2026
May 1
Capital/Financing Update
2026
Apr 7
Board/Management Information
2026
Apr 2
Capital/Financing Update
2026
Mar 25
Earnings Release
2026
Mar 25
Annual Report
2026
Mar 25